Dragonfly Therapeutics to Collaborate With AbbVie

Date : 11/20/2019 @ 2:44PM
Source : Dow Jones News
Stock : AbbVie Inc (ABBV)
Quote : 87.84  -0.89 (-1.00%) @ 12:59AM
After Hours
Last Trade
Last $ 87.90 ▲ 0.06 (0.07%)

Dragonfly Therapeutics to Collaborate With AbbVie

AbbVie (NYSE:ABBV)
Historical Stock Chart

1 Month : From Nov 2019 to Dec 2019

Click Here for more AbbVie Charts.

By Michael Dabaie

 

Dragonfly Therapeutics said it is in a collaboration with AbbVie Inc. (ABBV).

The biopharmaceutical company said it and AbbVie are in a multi-target research collaboration designed to advance Dragonfly's immunotherapies for autoimmune and oncology indications.

The deal grants AbbVie the option to license exclusive worldwide intellectual property rights to develop and commercialize products directed to specific targets using Dragonfly's TriNKET technology platform.

AbbVie will pay Dragonfly an upfront payment, future success-based milestone payments and royalties, Dragonfly said.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

November 20, 2019 09:29 ET (14:29 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest ABBV Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.